Catalog No.S1500 Synonyms: NSC-39470, SCH-4831
Molecular Weight(MW): 392.46
Betamethasone is a glucocorticoid steroid with anti-inflammatory and immunosuppressive properties.
Purity & Quality Control
Choose Selective Glucocorticoid Receptor Inhibitors
|Description||Betamethasone is a glucocorticoid steroid with anti-inflammatory and immunosuppressive properties.|
Betamethasone has a specific affinity for type II glucocorticoid receptors which are present in most brain regions. 
|In vivo||Betamethasone has direct vasoconstrictor effects on peripheral femoral resistance vessels in late gestation fetal sheep. Betamethasone exposure decreases cerebral blood flow (CBF) in all brain regions measured except the hippocampus after 24 hours of infusion in sheep.  Betamethasone reduces the activation of NF-kappaB and elevation of TNFalpha and IL-1beta, and induces the expression of IL-10 in the brain, all of which correlate with the changes of pain thresholds in rats.  Betamethasone exposure reduces synaptophysin-LI in the frontal neocortex, caudate putamen and hippocampus by 46.9%, 41.0% and 55.4%, respectively, that is not accompanied by irreversible neuronal damage in the fetal sheep brain.  Betamethasone modestly increases cytidylyltransferase (CT) mRNA, but does not alter the levels of immunoreactive enzyme in adult rat lung. Betamethasone decreases the activities of the sphingomyelin hydrolases: acid sphingomyelinase by 33% and of alkaline ceramidase by 21%.  Betamethasone injected at the time of nerve injury partially inhibits the development of neuropathic hyperalgesia and reduces the subsequent elevated levels of pro-inflammatory cytokines in the brain of rats, while stimulating the expression of the anti-inflammatory cytokine IL-10. |
-  Schwab M, et al. J Physiol,?000, 528(Pt 3), 619-632.
-  Xie W, et al. Ann Clin Lab Sci,?006, 36(1), 39-46.
-  Antonow-Schlorke I, et al. Neurosci Lett,?001, 297(3), 147-150.
|In vitro||DMSO||79 mg/mL (201.29 mM)|
|Ethanol||10 mg/mL (25.48 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02582177||Not yet recruiting||Tinea||Ache Laboratorios Farmaceuticos S.A.||August 2017||Phase 3|
|NCT03020199||Not yet recruiting||Plaque Psoriasis||Novartis Pharmaceuticals|Novartis||January 2017||Phase 4|
|NCT02897076||Recruiting||Neonatal Complications||Assistance Publique - Hôpitaux de Paris||January 2017||Phase 3|
|NCT02978976||Recruiting||Neonatal Respiratory Distress||Kasr El Aini Hospital||November 2016||Phase 4|
|NCT02939742||Not yet recruiting||PPROM|Respiratory Distress Syndrome in Premature Infants||The University of Texas Medical Branch, Galveston||November 2016||Phase 2|Phase 3|
|NCT02940002||Active, not recruiting||Psoriasis||Bayer||October 2016||Phase 1|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.